All In Biotech

Drug Trial Radar · NCT03070470

CiPA Phase 1 ECG Biomarker Validation Study

Comprehensive in Vitro Proarrhythmia Assay (CiPA) Clinical Phase 1 ECG Biomarker Validation Study (CiPA Phase 1 ECG Biomarker Study)

Last checked: Nov 20, 2026Latest source record: Jan 18, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

60

Actual

Start

Mar 14, 2017

Primary completion

Jun 26, 2017

Study completion Jun 26, 2017

Sponsor

Lead sponsor
Food and Drug Administration (FDA)Federal agency
Sponsor type
Federal agency
Collaborators
Spaulding Clinical Research LLC
First posted
Mar 3, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will assess whether exposure response analysis of the electrocardiographic QTc and J-Tpeakc intervals in Phase 1 clinical pharmacology studies can be used to confirm that drugs that predominantly block the potassium channel encoded by the human ether-à-go-go-related gene (hERG) with approximately equipotent late sodium and/or calcium block ("balanced ion channel" drugs) do not cause J-Tpeakc prolongation and that drugs that predominantly block hERG without late sodium or L-type calcium current block ("predominant hERG" drugs) cause QTc prolongation.

Conditions

  • Drug-induced QT Prolongation
  • Pharmacokinetics
  • Pharmacodynamics

Interventions

  • RanolazineDrug

    Ranolazine 1500 mg orally two times per day for 2.5 days

  • VerapamilDrug

    Verapamil 120 mg immediate release (IR) morning and afternoon doses on Days 1 and 2, 240 mg extended release (ER) evening dose on Days 1 and 2, and 120 mg IR morning dose on Day 3 (all oral doses)

  • Lopinavir / RitonavirDrug

    Lopinavir / Ritonavir 800 mg / 200 mg orally two times per day for 2.5 days

  • ChloroquineDrug

    Chloroquine 1000 mg on Day 1, 500 mg on Day 2, 1000 mg on Day 3 (all oral doses)

  • PlaceboDrug

    Placebo (administered orally)

  • Dofetilide and DiltiazemDrug

    In one period subjects receive Dofetilide 0.125 mg on Day 1, 0.375 mg on Day 3. In a second period (randomized cross-over) subject receive Diltiazem 120 mg IR morning dose on Day 8, 240 mg ER evening dose on Days 8 and 9, and 120 mg IR on Day 10 with coadministration of 0.25 mg dofetilide on Day 10.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline J-Tpeakc With "Balanced Ion Channel" Drugs (Ranolazine, Verapamil, Lopinavir / Ritonavir)Time frame: 3 days
  2. Change From Baseline QTc With "Predominant hERG" Blocking Drug (Chloroquine)Time frame: 3 days
  3. QTc Shortening From Calcium Block (Diltiazem) in the Presence of hERG Block (Dofetilide)Time frame: 3 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Spaulding Clinical Research

    West Bend, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.